Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short
Novartis has discontinued the development of Lu-NeoB, an experimental cancer therapy designed to seek out tumor cells and deliver targeted radiation.
Search results for "k-bio"
The Blood Cancer Decoy: Why Some Lymphoma Patients Stop Responding to Treatment
For patients diagnosed with aggressive blood cancers, receiving a proven targeted therapy offers a clear path toward a cure.
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven
Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.
Medical AI Can Explain Its Decisions—but Can Clinicians Trust Its Reasons?
Artificial intelligence in medical imaging can analyze brain magnetic resonance imaging scans not only to estimate...
EZH1 Mutation 'Locks' Cancer-Fighting Genes to Fuel Thyroid Tumors, Study Finds
Cancer cells do not grow simply by switching on genes that drive proliferation; they can also lock away genes that keep...
Celltrion Files for EU Approval of Cosentyx Biosimilar CT-P55, Targeting $6.7 Billion Autoimmune Market
Celltrion announced on the 24th that it has submitted a marketing authorization application to the European Medicines...
GSK Wins Early FDA Approval for Oral Lung Cancer Drug Jideytro Following $10.6 Billion Nuvalent Acquisition
A new oral therapy is now available for patients with ROS1-positive lung cancer whose disease has progressed following...
Daewoong Pharmaceutical Cuts Off Hospital Sales After Domestic Nabota Vials Surface in the U.S.
Daewoong Pharmaceutical announced on July 23 that it has severed supply transactions with a domestic medical...
HLB Innovation Expands Phase 1 CAR-T Trial Following Clean Early Safety Data
HLB Innovation announced on July 23 that its U.S. subsidiary, Verismo Therapeutics, has expanded the Phase 1 clinical...
Samsung Biologics Posts 586.4 Billion Won Q2 Profit, But Labor Uncertainty Looms
Samsung Biologics reported second-quarter revenue in the 1.3 trillion won range this year, a 30% increase from the same...